NRGene and Tel Aviv Sourasky Medical Center Collaborate on Parkinson's Genomes; Tel Aviv Sourasky Medical Center and NRGene research exploring protection again neurodegenerative disease

M2 PressWIRE |

Tel Aviv & Ness Ziona, Israel - - NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic analysis of Parkinson's disease (PD).

"Our collaboration with NRGene and use of its advanced technology allows us to do comprehensive genetic research on Parkinson's," said Professor Avi Orr-Urtreger, director of TASMC Genetic Institute. "The GenoMAGICTM system will allow us to characterize the genetics of the cohort completely and efficiently."

TASMC is leading successful combined clinical and genetics research aiming for better understanding, treatment, and prevention of Parkinson's disease. This 12-year-old collaboration between the department of Neurology (Prof.

Nir Giladi) and the Genetic Institute has already yielded international collaboration and support, as well as dozens of scientific publications. Currently, the study cohort in TASMC includes thousands of individuals and a wealth of data.

NRGene's GenoMAGICTM, a cutting-edge cloud-based genomic analytic system, will efficiently analyze the genomic data of a Parkinson's patients cohort and identify individuals' unique genomic makeup. Correlating genomic differences with disease phenotypes could reveal novel PD-related genes and the interaction between multiple genetic and environmental risk factors.

Stocks To Watch in 5G Wireless Growth Wave

"NRGene has already proven its ability to analyze large scale genomic datasets and accurately identify key genes and mutations affecting individuals," said NRGene CEO Gil Ronen. "We are proud that our unique genomic tools are supporting genetic studies of Parkinson's disease. The identification of genes involved in the development of the disease will improve our understanding of it and will potentially lead to new drug targets and treatment strategies."

About NRGene

NRGene is a genomic big data company developing cutting-edge software and algorithms to reveal the complexity and diversity of humans, plants and animals for supporting the most advanced medical research and sophisticated breeding programs. NRGene tools have already been employed by some of the leading seed companies worldwide as well as the most influential research teams in academia. www.nrgene.com.

NRGene Contact

Amy Kenigsberg

K2 Global Communications

amy@k2-gc.com

+1-913-440-4072 (+7 ET)

+972-9-794-1681 (+2 GMT)

TASMC contact

Miki Roll PhD, MBA

Deputy Director General for R&D

michalr@tlvmc.gov.il

Tel: 972-3-6974761

Fax: 972-3-6925739

www.tasmc.org.il

.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility
Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I

Market Movers

Sponsored Financial Content